GLP-1 Studies publishes sponsored, advertising-supported health information and is not a news organization. Content on this site is for general education only and is not medical advice, diagnosis, or treatment, and is not a substitute for care from a licensed professional. Articles may include illustrative bylines; member reviews are shown only when verified and consented, and are never fabricated or sourced from elsewhere. GLP-1 medications may have side effects; talk with a qualified provider about risks and benefits. Cited clinical-trial figures describe FDA-approved branded medications studied under medical supervision and are not a prediction or guarantee of individual results; they do not describe compounded products. Compounded medications are not FDA-approved and are not the same as Ozempic®, Wegovy®, Mounjaro®, or Zepbound®. Compounded medications are prepared by a state-licensed U.S. compounding pharmacy based on a provider's prescription. Compounded medications are not FDA-approved, and the FDA does not review them for safety, effectiveness, or quality before marketing. Ozempic® and Wegovy® are registered trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. Mediclab is not affiliated with, sponsored by, or endorsed by these companies; brand names are referenced for identification only. Advertised "/mo" prices (e.g., $199 semaglutide injection, $349 tirzepatide injection) are for the 6-month plan paid in one up-front payment (e.g., $1,194 for 6 months of semaglutide injection) — not month-to-month billing; month-to-month and 3-month plans cost more per month, require a licensed provider's prescription, and are HSA/FSA eligible. Completing an intake or making a payment does not guarantee a prescription, medication availability, or any specific outcome. Individual results vary. © 2026 GLP-1 Studies. All rights reserved.